Search research articles
Contact Us
Filters
Showing results (21-30 of 26) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 26 results.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
May 31, 2024
Abnormal eye movements increase as motor disabilities and cognitive impairments become more evident in Multiple Sclerosis: A novel eye-tracking study
Fernández Gerardo, Eizaguirre Bárbara, Gonzalez Cecilia, et al.
Multiple Sclerosis and Related Disorders
|
February 19, 2025
Eye movement deficits in Multiple Sclerosis: Characterizing executive problems as the disease worsens
Fernández Gerardo, Eizaguirre Bárbara, Gonzalez Cecilia, et al.
Frontiers in Immunology
|
August 25, 2023
Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation
Guo-Qing Tang, Yalan Tang, Ketki Dhamnaskar, et al.
Frontiers in Immunology
|
October 11, 2023
Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation
Guo-Qing Tang, Yalan Tang, Ketki Dhamnaskar, et al.
Journal of Medicinal Chemistry
|
November 10, 2020
Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design
Candice Alleyne, Rupesh P Amin, Bhavana Bhatt, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
September 12, 2020
Correction to: Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM)
Alonso Ricardo, Quarracino Cecilia, Eizaguirre Bárbara, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 26) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 26 results.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
May 31, 2024
Abnormal eye movements increase as motor disabilities and cognitive impairments become more evident in Multiple Sclerosis: A novel eye-tracking study
Fernández Gerardo, Eizaguirre Bárbara, Gonzalez Cecilia, et al.
Multiple Sclerosis and Related Disorders
|
February 19, 2025
Eye movement deficits in Multiple Sclerosis: Characterizing executive problems as the disease worsens
Fernández Gerardo, Eizaguirre Bárbara, Gonzalez Cecilia, et al.
Frontiers in Immunology
|
August 25, 2023
Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation
Guo-Qing Tang, Yalan Tang, Ketki Dhamnaskar, et al.
Frontiers in Immunology
|
October 11, 2023
Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation
Guo-Qing Tang, Yalan Tang, Ketki Dhamnaskar, et al.
Journal of Medicinal Chemistry
|
November 10, 2020
Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design
Candice Alleyne, Rupesh P Amin, Bhavana Bhatt, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
September 12, 2020
Correction to: Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM)
Alonso Ricardo, Quarracino Cecilia, Eizaguirre Bárbara, et al.
Page
of 3